Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rigel: Merck Serono Exercises Option In Japanese Territory (Japan)

This article was originally published in PharmAsia News

Executive Summary

Rigel Pharmaceuticals Inc. reports that Merck KGaA's Merck Serono division exercised its option to add the Japanese territory to its Aurora kinase collaboration that includes Rigel's lead product, R763/AS703569. Rigel will receive a $3 million payment in exchange for the extended development and marketing rights. In October 2005, Rigel and Merck Serono signed a worldwide collaboration, excluding Japan, to develop R763/AS703569 and other Aurora kinase inhibitors. R763/AS703569 has exhibited anti-tumor activity against a range of cancer cell lines. (Click here for more - May Require Paid Subscription
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC065804

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel